Oppenheimer Raises United Therapeutics (NASDAQ:UTHR) Price Target to $400.00

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by equities researchers at Oppenheimer from $375.00 to $400.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 56.78% from the stock’s current price.

A number of other equities research analysts also recently weighed in on UTHR. Wedbush reiterated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. HC Wainwright reissued a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $306.00.

United Therapeutics Trading Up 8.9 %

Shares of UTHR stock opened at $255.14 on Thursday. The firm has a 50 day moving average price of $234.62 and a two-hundred day moving average price of $228.81. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $11.32 billion, a PE ratio of 12.86 and a beta of 0.54. United Therapeutics has a 12-month low of $204.44 and a 12-month high of $261.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same period in the previous year, the business earned $2.67 earnings per share. The firm’s quarterly revenue was up 25.1% on a year-over-year basis. As a group, analysts predict that United Therapeutics will post 23.45 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $235.35, for a total transaction of $847,260.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,595.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total transaction of $847,260.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,595.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,190 shares of company stock valued at $32,643,561. 12.50% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Institutional investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale grew its stake in shares of United Therapeutics by 54.4% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after purchasing an additional 33,338 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of United Therapeutics by 155.2% in the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock worth $8,427,000 after purchasing an additional 23,532 shares during the last quarter. Duality Advisers LP grew its stake in shares of United Therapeutics by 56.1% in the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of United Therapeutics in the fourth quarter worth $2,903,000. Finally, O Shaughnessy Asset Management LLC grew its stake in shares of United Therapeutics by 4.9% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 107 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.